The Cardiology Advisor

Mavacamten Significantly Improves Symptomatic oHCM in Adolescent Population

SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
Seeking Alpha

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

– Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated ...
Nasdaq

Cytokinetics Announces Progression of REDWOOD-HCM to Cohort 2

Interim Analysis of Data from Cohort 1 Demonstrate Substantial Effects of CK-274 to Reduce LVOT Gradient in Patients with Obstructive Hypertrophic Cardiomyopathy with No Dose Interruptions Due to Left ...
Nature

Hypertrophic obstructive cardiomyopathy: a comparison of treatment options

Asymmetrical septal hypertrophy that causes a left-ventricular outflow tract (LVOT) gradient is a common feature of hypertrophic obstructive cardiomyopathy (HCOM). Septal myectomy is the standard ...